First AD

Second AD

Future Perspectives in KRAS G12C-Mutated NSCLC

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC

OncLive Insights

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.

The State of Targeted Therapies in NSCLC

Frontline Treatments for KRAS G12C-Mutation mNSCLC

Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

Disease Progression Beyond Frontline KRAS G12C Inhibitors

CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

Practical Management of Hepatotoxicity in KRAS G12C Inhibitors